|

ESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population

RECRUITINGSponsored by Hellenic Cooperative Oncology Group
Actively Recruiting
SponsorHellenic Cooperative Oncology Group
Started2025-05-13
Est. completion2027-05-15
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The goal of this observational study is to assess the prevalence of ESR1 mutations in patients with metastatic hormone receptor-positive/HER2-negative breast cancer in Greece and evaluate the associations of these mutations with disease characteristics, clinical outcomes and real-world treatment patterns. This study will include participants who have already undergone ESR1 testing as part of their standard medical care. Patient real-world data will be extracted by the patient's medical records. No additional procedures or visits beyond routine care will be required. Data will be collected from routine clinical visits and standard-of-care treatment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Male or female patients, regardless of race, residing in Greece, aged 18 years or older at the start of treatment.

Patients with histologically confirmed metastatic breast cancer with positive hormone receptors and negative HER2 status.

Patients undergoing ESR1 mutation testing.

Exclusion Criteria:

* Patients with metastatic hormone receptor-positive breast cancer who have not undergone ESR1 mutation testing.

Conditions5

Breast CancerBreast Cancer (Locally Advanced or Metastatic)CancerESR1 Gene MutationHormon Receptor Positive Breast Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.